Schistosomiasis rarely makes headlines outside the countries it affects, yet it sits on the World Health Organization’s official list of neglected tropical diseases (NTDs) alongside taeniasis and cysticercosis, and it anchors one of the roadmap’s more concrete 2030 elimination targets. For a publication built on the tradition of tropical- and global-health reporting, the disease is a useful case study in how the WHO actually defines "progress" against an NTD: not as a vague aspiration, but as a measurable threshold tied to a specific year.
What Schistosomiasis Is, and Why Snails Matter
Schistosomiasis is caused by parasitic blood flukes and is transmitted when larval forms released by freshwater snails penetrate human skin during contact with infested water — wading, bathing, washing clothes, or agricultural work in rivers, lakes, and irrigation channels. The cycle closes when infected people contaminate the same freshwater sources with faeces or urine carrying parasite eggs, which hatch and continue the chain through the snail population. That dependence on a freshwater intermediate host is precisely why the disease clusters in communities lacking safe drinking water and adequate sanitation, and why the WHO treats water, sanitation and hygiene (WASH) infrastructure as inseparable from the medical response.
Where the Burden Falls Heaviest
Schistosomiasis is present across tropical and subtropical regions, but the distribution is far from even. Africa carries the large majority of the global burden — accounting for roughly 84% of prevalence, 88% of disability-adjusted life years (DALYs), and 87% of deaths attributed to the disease. Asia, the Caribbean, and South America report cases as well, and a distinct form, schistosomiasis japonica, is documented in China, the Philippines, and Indonesia. This regional concentration is a large part of why the disease qualifies as "neglected" in the technical sense the WHO uses the term: it is a serious, chronic condition affecting populations with the least political and market leverage to demand attention or treatment.
Reading the Burden Numbers
The scale involved is easy to understate. In 2024, an estimated 253.7 million people required preventive treatment for schistosomiasis, and reported treatment reached just over 100.5 million of them — a gap that illustrates how far coverage still has to travel. Separately, global burden of disease estimates for 2021 put prevalence at roughly 151.4 million people, alongside more than 1.7 million DALYs and close to 13,000 deaths attributed to the disease that year. The two figures measure different things (treatment need versus modeled prevalence and mortality), but together they describe a disease that is simultaneously widespread, chronic, and under-resourced relative to its scale.
Schistosomiasis at a Glance
| Metric | Figure |
|---|---|
| People requiring preventive treatment (2024) | 253.7 million |
| People reported treated (2024) | ~100.5 million |
| Global prevalence estimate (2021) | ~151.4 million |
| Share of prevalence, DALYs, and deaths in Africa | ~84-88% |
| Primary transmission route | Freshwater snail-released larvae penetrating skin |
The WHO’s 2030 Targets
The WHO’s NTD roadmap for 2021-2030 sets two distinct benchmarks for schistosomiasis, and the distinction matters for anyone trying to interpret country-level progress reports. The first and broader goal is elimination as a public health problem in all endemic countries by 2030 — defined specifically as bringing the prevalence of heavy-intensity infections below 1%, not eliminating the parasite outright. The second, narrower goal is interruption of transmission — the absence of infection in humans — in a selected subset of countries by the same year. A country can therefore claim it has met the "elimination as a public health problem" target while the parasite is still circulating at low intensity in its population; the roadmap treats that as a legitimate milestone rather than a loophole, because it reflects a genuine reduction in disease burden and severe outcomes.
What the Roadmap Asks Beyond a Pill
The primary tool for hitting these targets is preventive chemotherapy: periodic, large-scale treatment with praziquantel delivered to at-risk populations, including an expansion to preschool-aged children who were historically excluded from mass drug campaigns. In communities where prevalence exceeds 10%, the WHO recommends annual treatment with at least 75% coverage across all age groups from age two upward. But the roadmap is explicit that chemotherapy alone will not reach the 2030 targets. It calls for a comprehensive approach spanning safe drinking water access, adequate sanitation, hygiene education, environmental management, and snail control, coordinated across the WASH, vector-control, animal-health, and environmental-management sectors rather than run as a standalone health-ministry program. The roadmap also flags gaps that still need closing: standardized point-of-care diagnostic tools and alternatives to praziquantel, since a single-drug strategy carries long-term risk if resistance ever emerges at scale.
Why the Framing Matters
Schistosomiasis is a useful lens on the WHO’s NTD list precisely because it resists a simple narrative. It is not a disease that will be eradicated in the way smallpox was; the roadmap’s own definition of success allows for continued low-level parasite presence as long as heavy infections and their consequences drop below a defined threshold. That distinction — control versus interruption, prevalence versus severity — is the kind of detail that gets lost when the disease is mentioned only in passing alongside taeniasis, cysticercosis, and the rest of the WHO’s twenty-plus NTD list. Understanding it on its own terms is a reasonable starting point for following whether the 2030 targets are actually met, or simply restated for the next roadmap cycle.
For readers tracking the broader NTD portfolio, schistosomiasis is also a reminder that "elimination" is not a single fixed concept across the WHO’s list. Some diseases on the roadmap are pursued toward outright eradication; others, like schistosomiasis, are pursued toward a defined reduction in severe disease while low-level transmission may persist for years afterward. Reading roadmap progress reports with that distinction in mind is the difference between a headline figure and an accurate picture of where control efforts actually stand.